Form 4: Pfizer R&D President Receives Performance Share Awards

Pfizer's President of R&D, Christoffel Boshoff, received performance share awards and had shares withheld for tax obligations.

Summary

• Christoffel Boshoff, President, R&D at Pfizer Inc. (PFE), acquired 13,383 shares of common stock on February 25, 2026.
• This acquisition represents the earn-out of performance share awards, including dividend equivalents, with a transaction price of $0.0000 per share.
• Concurrently, 6,833 shares of common stock were disposed of on February 25, 2026, at a price of $27.09 per share.
• The disposition was for the purpose of withholding shares to satisfy tax obligations related to the earn-out of the performance share awards.
• Following these transactions, Boshoff directly beneficially owns 161,379 shares of common stock.
• Additionally, Boshoff indirectly beneficially owns 709 shares of common stock through a Rule 16b-3 Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the successful vesting of performance-based compensation for a key executive. While shares were disposed for tax, the underlying award indicates achieved performance.

Positives

• The reporting person received a significant number of shares (13,383) as an earn-out from performance share awards, indicating successful achievement of performance metrics.
• The receipt of performance share awards aligns the executive's interests with long-term shareholder value.

Negatives

• A portion of the earned shares (6,833 shares) was withheld to cover tax obligations, resulting in a reduction of the net shares received.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that this Form 4 filing represents a routine insider transaction related to executive compensation. The earn-out of performance share awards is a common practice in the pharmaceutical industry to incentivize long-term executive performance and align management interests with shareholder returns. The subsequent withholding of shares for tax purposes is a standard procedure for such equity awards.

Stakeholder Impact

• Shareholders: The transaction reflects the company's executive compensation structure, aligning executive incentives with company performance. It does not directly impact the company's operational or financial performance.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The reporting person, Christoffel Boshoff, received a significant portion of his performance-based compensation, reinforcing his financial stake in the company.

Key Dates

Keywords

Pfizer, PFE, Insider Transaction, Form 4, Executive Compensation, Performance Shares, Stock Award, R&D, Tax Withholding